AHR

Analyst Note: American Healthcare REIT, Inc. (AHR)

Date: 2026-06-13 Current Price: $46.52

1. Structural Readiness

• State: Context-only.
• Conservative Entry: Not yet defined (awaiting confirmed breakout above the coil resistance).
• Aggressive/Pre-Breakout Entry: Not recommended for a "forming" coil without a confirmed catalyst; the current price ($46.52) represents the current market level, not a specific entry trigger.
• Breakout Level: Not yet established (requires price to close above the coil resistance).
• Extension: Not applicable (price is within the coil range, not extended above a breakout).
• ATR Context: Current ATR is 2.9% (productive). This sits within the "productive" range, suggesting manageable volatility for position sizing, though it is below the historical "sweet spot" of 4–6% for high-momentum breakouts.

2. Thesis Layer

• Thesis Classification: Tactical / Setup-Led.
• Macro Thesis: There is no named secular thesis attached to this specific setup at this date. The analysis must rely strictly on the quality of the technical setup (the forming coil) and the underlying business fundamentals provided in the evidence. No external macro narratives should be invented to support the trade.

3. Business Overview

American Healthcare REIT, Inc. (AHR) is a self-managed Real Estate Investment Trust (REIT) focused on clinical healthcare real estate. As of the latest filings (May 2026), the company operates through four reportable segments:

• ISHC (Integrated Senior Health Campuses): A core growth engine utilizing RIDEA structures to capture operational upside.
• SHOP (Senior Housing Operating Properties): A high-growth segment.
• OM (Outpatient Medical): Stable lease segment.
• Triple Net Lease: Income-generating properties.

Key Operational Metrics (as of Q1 2026 / May 2026):

• Portfolio Scale: As of March 31, 2026, the company owned/operated 343 buildings with approximately 22,651,000 square feet of gross leasable area (GLA) at an aggregate contract purchase price of $5.6 billion.
• Acquisition Activity: Year-to-date (through May 2026), the company closed $249.2 million in new acquisitions, all within the SHOP segment. In Q1 2026 alone, they acquired three land parcels in Kentucky and Ohio for $4.066 million for future ISHC development and seven senior housing properties for cash.
• Organic Growth: The company reported total portfolio same-store NOI growth of 12.1% for the quarter ended March 31, 2026, marking the ninth consecutive quarter of double-digit growth.
• Management: The firm is self-managed with a team of over 100 professionals, many with collaboration history dating back to 2006.

4. Archetype and Conviction

• Archetype: Growth Leader.
• *Fit:* The company demonstrates consistent double-digit same-store NOI growth (12.1% reported, 11-15% guidance for Trilogy/SHOP), aggressive M&A activity ($249.2M YTD), and a clear demographic tailwind (aging 80+ population) that management cites as a primary driver.
• Valuation Context:
• Forward consensus EPS (FY1) is $0.56975; FY2 is $0.81367.
• At a current price of $46.52, the FY1 forward P/E is approximately 81.6x, and FY2 is approximately 57.1x. This suggests the market is pricing in significant future growth, consistent with a "Growth Leader" archetype rather than a deep value or income play.
• Conviction Stack:
• Thesis Strength: Low (Tactical only, no macro thesis).
• Evidence Quality: High. Multiple primary sources (earnings transcripts, SEC filings) confirm strong organic growth, active acquisition, and clear management guidance.
• Rerating Potential: High, contingent on the continuation of the 12%+ same-store NOI growth and successful deployment of capital into the SHOP and ISHC segments.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen the Case:
• A confirmed price close above the coil resistance (breakout) with volume.
• Management raising the full-year 2026 same-store NOI guidance beyond the current 11-15% (Trilogy) and 15-19% (SHOP) ranges.
• Confirmation of the "historic lows" in new supply continuing to drive pricing power.
• What Would Invalidate the Case:
• A significant deviation from the stated guidance (e.g., same-store NOI growth dropping below 5%).
• Failure to close acquisitions or a halt in the SHOP segment growth.
• Gaps in Evidence:
• Breakout Level: The specific resistance level required for a confirmed breakout is not defined.
• Debt Maturity Schedule: While the balance sheet is implied to be healthy, specific debt maturity walls or leverage ratios are not detailed in the provided snippets.
• Capex Details: While land acquisitions are noted, specific capital expenditure requirements for the ISHC development pipeline are not quantified.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Ninth consecutive quarter of double-digit same-store NOI growth (12.1%); $249.2M in SHOP acquisitions YTD; Management guidance of 15-19% SHOP growth for 2026. Key risks: Setup is in "forming" state with no confirmed breakout; High forward P/E multiples (81x FY1) imply high growth expectations; Lack of named macro thesis reduces conviction buffer. Expected path: Management expects continued demographic-driven demand and low new supply to sustain 11-19% segment growth; price likely to consolidate until a catalyst triggers a breakout above the coil resistance. Expected horizon: 3 to 6 months for a potential breakout confirmation or setup invalidation.